We may speculate that the post-therapy expansion of a CD11b+GR1+ MDSC population may represent an additional immune-regulatory mechanism, which may explain the lower efficacy of combined immunotherapy, in the NXS2 NB model. This evidence concerns the gene ITGAM and neuroblastoma.